Table 3.

All-cause, CVD, and non-CVD mortality in participants with diabetes, as well as cardiovascular outcomes and mortality in participants with diabetes by baseline eGFR for chlorthalidone, amlodipine, and lisinopril antihypertensive treatment groups

eGFRTotal Number of Events/Participants10-Yr Rate/100 ParticipantsHR (95% CI)PHR (95% CI)P
CALCALA Compared with CL Compared with C
All-cause mortality2292/57231329/34071270/332538.537.236.40.96 (0.90–1.03) 0.230.94 (0.88–1.01) 0.10
 ≥90560/1794326/1104320/107430.228.229.20.93 (0.81–1.06) 0.280.95 (0.83–1.09) 0.44
 60–891169/2976674/1755659/172237.336.336.00.96 (0.87–1.06) 0.400.97 (0.89–1.07) 0.58
 <60563/953329/548291/52957.558.052.61.04 (0.90–1.19) 0.620.90 (0.78–1.03)0.13
CVD mortality102359755219.418.317.90.97 (0.87–1.07) 0.510.92 (0.83–1.02) 0.11
 ≥9022813812513.912.712.60.96 (0.78–1.19) 0.740.91 (0.73–1.13) 0.39
 60–8953030828919.118.117.80.97 (0.84–1.12) 0.660.94 (0.82–1.09) 0.42
 <6026515113832.032.029.71.01 (0.82–1.23) 0.950.90 (0.73–1.11) 0.33
Non-CVD mortality118068466022.221.821.10.96 (0.87–1.05) 0.380.95 (0.87–1.05) 0.31
 ≥9031117717918.016.917.70.91 (0.75–1.09) 0.290.95 (0.79–1.15) 0.61
 60–8958934834120.921.420.60.98 (0.86–1.12) 0.801.00 (0.87–1.14) 0.99
 <6028015914035.935.330.61.01 (0.83–1.23) 0.920.86 (0.71–1.06) 0.16
CHD, total710/3802401/2233385/219422.520.820.20.94 (0.83–1.06) 0.290.93 (0.82–1.06) 0.27
 ≥90168/104291/63184/61519.115.816.10.86 (0.67–1.11) 0.240.83 (0.64–1.07) 0.16
 60–89362/2026222/1188207/117921.021.519.91.02 (0.87–1.21) 0.791.00 (0.84–1.18) 0.97
 <60180/73488/41494/40033.027.928.30.86 (0.66–1.11) 0.240.92 (0.72–1.19)0.54
CVD, total148388782144.943.642.51.00 (0.92–1.09) 0.930.96 (0.88–1.04) 0.33
 ≥9036622020140.136.837.30.96 (0.81–1.14) 0.650.93 (0.78–1.10) 0.41
 60–8976046042542.442.840.41.02 (0.91–1.15) 0.730.97 (0.89–1.09) 0.62
 <6035720719560.357.357.21.04 (0.88–1.24) 0.640.99 (0.83–1.18) 0.89
Stroke, total46327428515.415.116.70.98 (0.85–1.14) 0.821.07 (0.92–1.24) 0.40
 ≥90105707112.412.314.41.06 (0.78–1.43) 0.721.16 (0.86–1.57) 0.34
 60–8924813915515.114.616.40.93 (0.76–1.15) 0.501.08 (0.89–1.33) 0.43
 <60110655921.622.422.81.07 (0.79–1.45) 0.670.95 (0.69–1.30) 0.75
HF, total57939133720.020.819.71.15 (1.01–1.31) 0.031.01 (0.88–1.15) 0.91
 ≥90142897917.616.115.90.99 (0.76–1.30) 0.970.94 (0.71–1.24) 0.65
 60–8929720416718.520.218.51.19 (0.99–1.42) 0.060.98 (0.81–1.19) 0.85
 <60140989129.031.130.21.28 (0.98–1.65) 0.071.17 (0.90–1.52) 0.26
  • The Modified Diet in Renal Disease equation was used to estimate baseline GFR. The mortality cohort included 12,455 participants whereas the morbidity and mortality cohort included 8229 participants. HF indicates those participants with heart failure who were hospitalized or had a fatal event; CVD indicates CVD mortality or first hospitalized nonfatal CVD event such as MI, stroke, or HF; and ESRD indicates start of dialysis or renal transplant. CVD mortality includes death due to CHD, stroke, HF, or other CVD. There were 4891 deaths, 2172 due to CVD, 2524 due to non-CVD causes, and 195 unknown causes. CVD, cardiovascular disease; eGFR, estimated GFR; C, chlorthalidone; A, amlodipine; L, lisinopril; HR, hazard ratio; 95% CI, 95% confidence interval; CHD, coronary heart disease; HF, heart failure.